Clinical trial

MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC

NCT04633564

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-01-21

PhasePHASE3

Study timeline

Study start (actual)2017-01-21Date precision: day

Registry last updated2022-03-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC Stage IVunresolved

Interventions

Bevacizumab as MYL-1402OBIOLOGICAL

Bevacizumab as AvastinBIOLOGICAL

Sponsors & collaborators

Mylan Pharmaceuticals Inclead sponsor

Mapped research locations

Saint PetersburgRussia6 BudapestHungary2 BucharestRomania2 Kaohsiung CityTaiwan2 BarcelonaSpain1 TaipeiTaiwan1 MoscowRussia1 TaichungTaiwan1 AnkaraTurkey (Türkiye)1 PoznanPoland1 IzmirTurkey (Türkiye)1 DebrecenHungary1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04633564 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.